Cargando…

Estimating the budget impact of orphan medicines in Europe: 2010 - 2020

BACKGROUND: Orphan drugs are a growing issue of importance to European healthcare policy makers. The success of orphan drug legislation in Europe has resulted in an increasing number of licensed medicines for rare diseases, and many more yet unlicensed products have received orphan drug designation....

Descripción completa

Detalles Bibliográficos
Autores principales:	Schey, Carina, Milanova, Tsveta, Hutchings, Adam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191371/ https://www.ncbi.nlm.nih.gov/pubmed/21951518 http://dx.doi.org/10.1186/1750-1172-6-62

Ejemplares similares

Estimating the budget impact of orphan drugs in Sweden and France 2013–2020
por: Hutchings, Adam, et al.
Publicado: (2014)

An analysis of orphan medicine expenditure in Europe: is it sustainable?
por: Mestre-Ferrandiz, Jorge, et al.
Publicado: (2019)

Impact of orphan drugs on Latvian budget
por: Logviss, Konstantins, et al.
Publicado: (2016)

Principles for consistent value assessment and sustainable funding of orphan drugs in Europe
por: Gutierrez, Laura, et al.
Publicado: (2015)

Comparing access to orphan medicinal products in Europe
por: Zamora, Bernarda, et al.
Publicado: (2019)

Access to Affordable Orphan Medicines in Europe: An EHA Position Paper
por: Merlini, Giampaolo, et al.
Publicado: (2020)

Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
por: Brabers, Anne EM, et al.
Publicado: (2011)

Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review
por: Abdallah, Khadidja, et al.
Publicado: (2021)

Global and regional estimates of orphans attributed to maternal cancer mortality in 2020
por: Guida, Florence, et al.
Publicado: (2022)

Trends in orphan drug use and spending among children and adolescents during 2010–2020 in Korea
por: Oh, Jung Yeon, et al.
Publicado: (2022)

2010 Budget - Scale of Contributions
Publicado: (2009)

Availability and Accessibility of Orphan Medicinal Products to Patients in Slovakia in the Years 2010–2019
por: Foltanova, Tatiana, et al.
Publicado: (2022)

Precision Medicines’ Impact on Orphan Drug Designation
por: Mueller, Christine M., et al.
Publicado: (2019)

Revised 2020 Budget
Publicado: (2020)

Revised 2020 Budget
Publicado: (2020)

The scientific activities of CERN and budget estimates for the years 2003-2010 - Preliminary orientations
Publicado: (2002)

The scientific activities of CERN and budget estimates for the years 2003-2010 - preliminary orientations
Publicado: (2002)

Scientific Activities and Budget Estimates for 2007 and provisional projections for the years 2008-2010
Publicado: (2006)

Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties
por: Pontes, Caridad, et al.
Publicado: (2018)

Estimating the impact of expanded access to antiretroviral therapy on maternal, paternal and double orphans in sub-Saharan Africa, 2009-2020
por: Anema, Aranka, et al.
Publicado: (2011)

2010 Budget - Preliminary Scale of Contributions
Publicado: (2009)

A comparative study of orphan drug prices in Europe
por: Young, Katherine Eve, et al.
Publicado: (2017)

The Scientific Activities of CERN and Budget Estimates for the Years 2006-2009 and Projections for the Year 2010
Publicado: (2005)

2020 Budget: Scale of Contributions
Publicado: (2019)

2020 Budget: Scale of Contributions
Publicado: (2019)

Estimating the clinical cost of drug development for orphan versus non-orphan drugs
por: Jayasundara, Kavisha, et al.
Publicado: (2019)

Affordability of oncology drugs: accuracy of budget impact estimations
por: Geenen, Joost W., et al.
Publicado: (2019)

The Scientific Activities of CERN and Budget Estimates for the Years 2004-2007 and Projection For the Years 2008-2010
Publicado: (2003)

The Scientific Activities of CERN and Budget Estimates for the Years 2003-2006, with a Projection until 2010
Publicado: (2002)

The Scientific Activities of CERN and Budget Estimates for the Years 2005-2008 and Projection for the Years 2009-2010
Publicado: (2004)

The scientific activities of CERN and budget estimates for the years 2003-2006 and projection for the years 2007-2010
Publicado: (2002)

Europe prompts budget cuts for research councils
Publicado: (1995)

Descriptive Overview of Pertussis Epidemiology Among Older Adults in Europe During 2010–2020
por: Bahar, Enas, et al.
Publicado: (2022)

The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
por: Kawalec, Paweł, et al.
Publicado: (2016)

Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs
por: Schey, C., et al.
Publicado: (2017)

Evaluation of clinical trials done for orphan drugs versus nonorphan drugs in infectious diseasesan eleven year analysis [2010-2020]
por: Kudyar, Palvi, et al.
Publicado: (2023)

Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen
por: Giannuzzi, Viviana, et al.
Publicado: (2017)

Making Sure That Orphan Incentives Tip the Right Way in Europe
por: Horgan, Denis, et al.
Publicado: (2022)

Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007–2019)
por: Lee, Se Hee, et al.
Publicado: (2020)

Budget of the Organization for the 56th Financial Year 2010
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_970d7b0417ifohd17i8qf994j7